This study is designed to determine the pharmacokinetic and pharmacodynamic response of dorzagliatin 75 mg twice daily following 7-day administration in individuals with pancreatic insufficient cystic fibrosis and abnormal glucose tolerance when compared to randomized, double-blind 7-day administration of placebo in a cross-over fashion. We hypothesize that dorzagliatin administration will result in significant drug concentrations and improved glucose tolerance, early-phase insulin secretion, glucagon suppression, and hepatic glycogen storage assessed during a standardized mixed-meal tolerance test.

开始日期2025-07-01

申办/合作机构

University of Pennsylvania

NCT06976658

/ Not yet recruiting临床2期IIT

Evaluating a Novel, Allosteric Glucokinase Activator in Monogenic Diabetes Secondary to Inactivating Glucokinase Mutations: a Randomised, Cross-over Trial

Evaluating a novel, allosteric glucokinase activator in monogenic diabetes secondary to inactivating glucokinase mutations: a randomised, cross-over trial

开始日期2025-05-28

申办/合作机构

香港中文大学

NCT06671340

/ Not yet recruitingN/AIIT

Effects of Repeated Dose of Dorzagliatin on Insulin Secretion, Glucagon Release and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes

A total of 30 subjects will be recruited 15 with intermediate hyperglycemia and 15 in the tyep 2 diabetes group respectively. Eligible participants will undergo hyperglycemic-clamp/oral glucose tolerance at baseline and after 4 weeks of dorzagliatin treatment.

开始日期2025-04-02

申办/合作机构

香港中文大学

100 项与多格列艾汀相关的临床结果

登录后查看更多信息

100 项与多格列艾汀相关的转化医学

登录后查看更多信息

100 项与多格列艾汀相关的专利（医药）

登录后查看更多信息

项与多格列艾汀相关的文献（医药）

2025-09-01·ANALYTICA CHIMICA ACTA

An innovative method for simultaneous separation and determination of monosaccharide and sugar alcohol isomers associated with glycometabolism in beagle plasma using gas chromatography-mass spectrometry

Article

作者: Zhang, Zunjian ; Xiao, Wen ; Tian, Yuan ; Liu, Qiaorong ; Ren, Haihui ; Han, Jiameng

BACKGROUND:

Tracking changes in plasma concentrations of monosaccharides and sugar alcohols related to glycometabolism, which plays a role as the main source of energy, is of great significance for the treatment of metabolic diseases. However, analysis of monosaccharides and sugar alcohols has always been a difficult task due to the high polarity of the polyhydroxy structure and the presence of a large number of isomers. So far, no suitable method has been developed for simultaneous determination of monosaccharides and sugar alcohols in beagle plasma.

RESULTS:

This work performed an innovative gas chromatography-mass spectrometry method for the simultaneous chromatographic separation and absolute quantification of 11 monosaccharides and sugar alcohols associated with glycometabolism. After derivatization, monosaccharides converted to be oxime acetylated derivatives and sugar alcohols transformed into acetylated derivatives. All analytes achieved good separation after chromatographic conditions were optimized, especially the selection of mid-polarity capillary column(6 % cyanopropyl phenyl and 94 % dimethyl polysiloxane). The improvement of derivatization efficiency through single factor and response surface optimization ensured a high sensitivity, with LOQ of each analyte in the range of 0.2-50 ng/mL. The established method was fully validated in terms of linearity and range, sensitivity, accuracy and precision, recovery, matrix effect, stability, dilution integrity and proved to be reliable, which was applied to the comparative study on hypoglycemic effect of two antidiabetic agents with different pharmacological mechanisms, dorzagliatin and metformin, as well as possible metabolic pathways affected by them.

SIGNIFICANCE:

This method solves the problems of multiple peaks after derivatization and frequent co-elution of analytes in previous analytical methods, significantly enhances derivatization efficiency of ketoses, which provides a promising approach for simultaneous analysis of aldose, ketose, and sugar alcohol. It offers new insights into a more comprehensive research on glycometabolism rather than merely focusing on glucose.

2025-09-01·Anti-inflammatory & anti-allergy agents in medicinal chemistry

Inclusive Drug Designing of Novel Indole Derivatives using Rationale, Pharmacophore Mapping and Molecular Docking

Article

作者: Mehra, Anuradha ; Sangwan, Rekha ; Sharma, Rahul ; Mehra, Aryan ; Mittal, Amit

Background::

The presence of insufficient insulin signaling in type 2 diabetes arises due to either insulin resistance or impaired insulin secretion, ultimately leading to elevated blood glucose levels, a condition known as hyperglycemia. Diabetes poses a pervasive worldwide challenge, with its prevalence steadily surging in both developed and developing nations. A promising avenue for improving the management of diabetes type 2 involves the exploration of glucokinase activators as an innovative therapeutic target. Notably, a recent breakthrough in this area has been the market approval granted by the Japanese FDA for the use of the innovative GKA, Dorzagliatin, in the treatment of diabetes type 2.

Objective::

To augment the management of diabetes type 2 and mitigate the undesirable side effects linked to prolonged use of conventional medications, this research endeavor sought to create innovative glucokinase activators.

Methods::

The ZINC database yielded a collection of 56 compounds, each showcasing a 40% structural similarity to 1-(phenylsulfonyl)-1H-indole-2-carboxylic acid. These compounds, all featuring the distinctive indole core, were meticulously selected for further investigation. Structural illustrations were crafted using ChemBioDraw Ultra, and 1.5.6 AutoDock Vina was for molecular docking. The Swiss ADME algorithm facilitated online log P predictions, while the software PKCSM was utilized to forecast the toxicity profiles of the leading compounds. DFT analysis was done to ensure the stability of compounds by using Gaussian 16 quantum chemistry software and Mulliken charge distributions used to optimize molecular geometries.

Results::

Among all the compounds, RS33 and RS37 exhibited the highest affinities for GK receptors, with the docking scores of -8.93 and -8.44 kcal/mol, respectively. These compounds follow Lipinski’s Rule, indicating promising absorption and excretion profiles through the gastrointestinal tract. Compared to standard drugs Dorzagliatin (GKA) and MRK (co-crystallized ligand), both RS33 and RS37 demonstrate no AMES toxicity, skin sensitization, and hepatotoxicity. RS43 is the most stable compound as it has high ΔE, η, and χ in DFT analysis.

Conclusion::

The novel-designed lead molecules demonstrate an enhanced pharmacokinetic profile, superior binding affinity, and minimal toxicity, based on computational study. These attributes make them promising candidates for further optimization as glucokinase activators.

2025-08-01·DIABETES

Functional and Mechanistic Explanation for the Unique Clinical Success of the Glucokinase Activator Dorzagliatin in the Treatment of Type 2 Diabetes

Article

作者: Sharp, Kim ; Zhu, Qiusha ; Zhou, Xue ; Doliba, Nicolai M. ; Meng, Shi ; Zhao, Fang ; Roman, Jeff ; Yuan, Yue ; Xu, Yue ; Chen, Li ; Li, Changhong ; Han, Dongna ; Wu, Shaowen

Article Highlights:

The type 2 diabetes (T2D) treatment dorzagliatin has achieved singular success among its drug class, known as glucokinase (GK) activators (GKAs). A comprehensive approach using human islet perifusions, enzyme kinetics, X-ray crystallography, and modeling studies revealed the unique mechanism by which dorzagliatin activates GK. Dorzagliatin dose-dependently reduces the glucose threshold for stimulation of insulin secretion and binds preferably to the closed form of GK, preventing overstimulation of the enzyme. A renewed interest in GKAs, coupled with modern tools to assess their molecular interactions with GK, should guide the future development of novel GKA treatments for T2D.

213

项与多格列艾汀相关的新闻（医药）

2025-07-29

·华领医药

【新闻】华领医药发布2025年度上半年正面盈利预告

2025年7月29日中国，上海华领医药（“公司”，香港联交所股份代号：2552）昨日宣布公司及其附属公司（以下简称“本集团”）上半年正面盈利预告。根据对本集团截至2025年6月30日止六个月（以下简称“报告期”）未经审计的管理账目作出的初步评估及本集团目前可得的资料，本集团预期在本报告期录得利润约人民币11.841亿元。上半年利润的预期增长主要得益于以下因素：2025年1月1日，公司终止与拜耳所订立的独家推广服务协议，未摊销合约负债人民币12.435亿元已拨回损益，并确认为本集团的收益。截至2025年6月30日止六个月，华领医药销售华堂宁®约176.4万盒，销售净额约人民币2.174亿元；2024年同期，华堂宁®销售量约为84.6万盒，销售净额约人民币1.027亿元，在每盒价格维持不变的情况下，实现销售额增长111.8%，证明商业化任务已顺利移交，且焕发新的活力。截至2025年6月30日止六个月的毛利约为人民币1.178亿元，毛利率约为54.2%；2024年同期毛利约为人民币4780万元，毛利率约46.5%。毛利率的增长主要由于生产效率及产量提高导致单位生产成本相应下降。陈力博士华领医药创始人、首席执行官华领医药创始人、首席执行官陈力博士表示：“2025年上半年，公司首次实现盈利，华堂宁®的增长势头强劲，公司药品市场销售团队的建立，加快了华堂宁®的市场推进速度，也为公司未来的持续盈利注入了信心。我们将继续通过研发创新和产能提升，探索华堂宁®在糖尿病个性化治疗以及糖尿病并发症等领域的市场潜力，惠及更多患者。”前瞻性声明本文包含有关华领医药以及产品未来预期、计划和前景的陈述。该等前瞻性陈述仅与本文作出该陈述当日的事件或资料有关，可能因未来发展而出现变动。除法律规定外，于作出前瞻性陈述当日之后，无论是否出现新资料、未来事件或其他情况，我们并无责任更新或公开修改任何前瞻性陈述及预料之外的事件。请仔细阅读本文并理解，由于各种风险、不确定性或其他法定要求我们的实际未来业绩或表现可能与预期有重大差异。关于华领华领医药（“本公司”）是一家总部位于中国上海的创新药物研发和商业化公司，在美国、中国香港设立了公司。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。公司核心产品华堂宁®（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖稳态失调。2022年9月30日，华堂宁®已获得中国国家药品监督管理局（NMPA）的上市批准，用于单独用药或者与二甲双胍联合用药，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于肾功能损伤的2型糖尿病患者的口服降糖药物。详情垂询华领医药网址：www.huamedicine.com投资者电邮：ir@huamedicine.com媒体电邮：pr@huamedicine.com新闻免责声明本材料，如为上下文论述的准确性和完整性，提及在中国上市的产品相关信息的，特别是标识或要求，应遵循中国监管机构批准的相关文件。另外，相关信息不应被解读为对任何药物或者诊疗方案的推荐或者宣传，亦不应替代任何医疗卫生专业人士的医疗建议，涉及医疗的相关事宜务必咨询医疗卫生专业人士。

2025-07-29

·华领医药

[News]Hua Medicine Released Positive Profit Alert for 2025 1H

July 29, 2025,Shanghai, ChinaHua Medicine (the "Company", Hong Kong Stock Exchange Stock Code: 2552) announced yesterday a positive profit alert for the first half of the year for the Company together with its subsidiaries. (the "Group").Based on a preliminary assessment of the unaudited management accounts of the Group for the six months ended June 30, 2025 (the "Current Reporting Period") and information currently available to the Group, the Group expects to record a profit of approximately RMB1,184.1 million for the Current Reporting Period.The expected growth in profit for the first half of the year is mainly attributed to the following factors:On January 1, 2025, the Company terminated the exclusive promotion service agreement with Bayer. The unamortized contract liabilities amounting to RMB1,243.5 million were released to profit or loss, and recognized as a gain by the Group.For the six months ended June 30, 2025, Hua Medicine sold approximately 1,764,000 packs of HuaTangNing(华堂宁®), representing approximately RMB217.4 million in net sales. During the same period in 2024, approximately 846,000 packs of HuaTangNing were sold, representing approximately RMB102.7 million in net sales. The difference represents a 111.8% increase in sales over a period during which the price per pack remained the same, which demonstrates that the transition of commercialization responsibility has been smooth and reinvigorated.Gross profit for the six months ended June 30, 2025 is expected to amount to approximately RMB117.8 million, while a gross profit of RMB47.8 million was reported in the same period in 2024. The expected significant increase in gross profit was attributable to increase in sales and improvement in gross margin. The Company will report an increase in gross margin to approximately 54.2% for the six months ended June 30, 2025 from 46.5% for the corresponding period in 2024. This was mainly due to increase in manufacturing efficiency and production volume that lead to corresponding reduction in unit production costs.Dr. Li ChenFounder and CEO of Hua MedicineDr. Li Chen, Founder and CEO of Hua Medicine, said, "In the first half of 2025, the Company achieved profitability for the first time. HuaTangNing has shown a strong growth momentum. The establishment of the Company's pharmaceutical marketing team has accelerated the market promotion of HuaTangNing and injected confidence into the Company's sustained profitability in the future. We will continue to explore the market potential of HuaTangNing in personalized treatment of diabetes and diabetic complications through R&D innovation and capacity improvement, so as to benefit more patients."Forward-Looking StatementsThis document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine (The "Company") is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (华堂宁®) (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing (华堂宁®) was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail: pr@huamedicine.comPress DisclaimerFor accuracy and completeness in context, information related to products marketed in China in this material, especially those identified or required, should comply with documents approved by Chinese regulatory authorities.Additionally, such information should not be interpreted as a recommendation or promotion of any drug or treatment, nor should it replace medical advice from healthcare professionals. For medical-related matters, please consult a healthcare professional.

临床研究

2025-07-28

·米内网

糖尿病“药王”跌超10%，扬子江、甘李……国产品牌突围！东阳光药、华东重磅新药火热来袭

精彩内容近期，糖尿病用药市场波澜再起。河南立诺制药|天津汉瑞药业的达格列净二甲双胍缓释片(Ⅰ)、达格列净二甲双胍缓释片(Ⅱ)、达格列净二甲双胍缓释片(Ⅲ)同日报产获CDE受理，诺和诺德的司美格鲁肽注射液新适应症获批。米内网数据显示，糖尿病用药（化+生）在2025年一季度中国零售药店终端销售额同比增长近9.00%。从品牌TOP20来看，“药王”跌超10%，扬子江药业、甘李药业等国产品牌突围。今年以来，糖尿病用药已有超过40个品种报产在审，其中，6个品种为新药，涉及东阳光药、华东医药、恒瑞医药等企业。重磅新品获批不断，奥萨、鲁南贝特发起冲击日前，诺和诺德的司美格鲁肽注射液新适应症获批，福安药业烟台只楚药业的硫辛酸片、湖南及正医药科技的二甲双胍恩格列净片(Ⅰ)、深圳奥萨制药的恩格列净片、鲁南贝特制药的利格列汀片等均以新分类报产先后获批上市。今年以来糖尿病用药（化+生）新药获批情况来源：米内网中国申报进度（MED）数据库今年以来，糖尿病用药（化+生）已有超过90个受理号获批上市，涉及品种超过30个。其中，信达生物制药(苏州)的玛仕度肽注射液、山东盛迪医药的瑞格列汀二甲双胍片(Ⅰ)和瑞格列汀二甲双胍片(Ⅱ)、上海银诺医药的依苏帕格鲁肽α注射液、石药欧意药业的普卢格列汀片为1类新药。糖尿病“药王”跌超10%，扬子江、甘李……国产品牌突围米内网数据显示，糖尿病用药（化+生）在近年中国零售药店（城市实体药店+网上药店）终端市场规模持续扩容，2024年销售额突破130亿元，2025年一季度同比增长近9%。其中，城市实体药店是主力销售渠道，网上药店则保持快速增长。从一级集团TOP20来看，跨国药企占据前列位置，诺和诺德、阿斯利康、默克、默沙东、礼来排前五位。值得一提的是，国内药企仅远大健康和扬子江药业在前十之列，而甘李药业、华领医药、正大制药等均有双位数增速。2025年一季度中国零售药店终端糖尿病用药（化+生）小类格局来源：米内网格局数据库GLP-1受体激动剂、胰岛素及其类似药、SGLT2抑制剂是TOP3治疗小类，口服降糖药复方增速最快，同比增长超过35%。从剂型来看，片剂一枝独秀，注射剂位居第二，合计市场份额占比超过90%。从在销品种数量来看，涉及产品超过140个，超过600个品牌。2025年一季度中国零售药店终端糖尿病用药（化+生）品牌TOP20来源：米内网格局数据库注：增长率不足10%用*表示品牌TOP20中，4个销售额超过1亿元，诺和诺德的司美格鲁肽注射液和阿斯利康的达格列净片超过4亿元，默克的盐酸二甲双胍片超过2亿元，默沙东的磷酸西格列汀片超过1亿元。从增速来看，礼来的替尔泊肽注射液暴涨1036.37%，诺和诺德的德谷胰岛素注射液和德谷胰岛素利拉鲁肽注射液增速均超过50%。4个上榜的国产品牌均为正增长，甘李药业的甘精胰岛素注射液增速最快，达28.97%；华领医药(上海)的多格列艾汀片和杭州中美华东制药的吡格列酮二甲双胍片(15mg/500mg)增速均超过10%。此外，诺和诺德的司美格鲁肽注射液则是TOP20中跌幅最大的品牌。从集团层面来看，诺和诺德最多，有司美格鲁肽注射液、门冬胰岛素30注射液、德谷门冬双胰岛素注射液等7个品种上榜；默沙东和赛诺菲各有2个品种上榜。近年中国零售药店终端司美格鲁肽注射液销售情况（单位：万元）来源：米内网格局数据库司美格鲁肽注射液是诺和诺德研发的一款新型长效胰高糖素样肽-1（GLP-1）类似物，2021年中国获批进口上市。该产品在2024年中国零售药店终端突破20亿元的销售规模，2025年一季度下滑超过10%，是糖尿病用药（化+生）TOP1产品。目前，司美格鲁肽注射液仅有诺和诺德拥有生产批文，多家国内药企则纷纷出手布局。杭州九源基因、丽珠集团新北江制药、齐鲁制药、珠海联邦生物医药等国内药企报产在审，海南中和药业、山东新时代药业、浙江普洛康裕制药等超过20家企业获批临床。新药大爆发，东阳光药、华东、恒瑞火热来袭7月28日，CDE官网显示，河南立诺制药|天津汉瑞药业的达格列净二甲双胍缓释片(Ⅰ)、达格列净二甲双胍缓释片(Ⅱ)、达格列净二甲双胍缓释片(Ⅲ)同日报产获受理。在此之前，河北智恒医药科技的达格列净二甲双胍缓释片(Ⅰ)、河南大新药业的吡格列酮二甲双胍片、天津力生制药的达格列净片、湖南千金湘江药业的达格列净二甲双胍缓释片(Ⅰ)和达格列净二甲双胍缓释片(Ⅲ)等产品先后提交上市申请。今年以来糖尿病用药（化+生）新药报产在审情况来源：米内网中国申报进度（MED）数据库今年以来，糖尿病用药（化+生）已有超过160个受理号报产在审，涉及品种超过40个，其中，6个品种为新药，东阳光药（德谷门冬双胰岛素注射液、德谷胰岛素注射液）和华东医药（司美格鲁肽注射液、德谷胰岛素注射液）各有2个产品报产在审，舒地胰岛素注射液则是恒瑞医药首个胰岛素制剂。2022年至今，糖尿病用药（化+生）新药共有16个品种报产在审。资料来源：米内网数据库、公司公告等注：米内网《中国城市实体药店药品终端竞争格局》，统计范围是：全国地级及以上城市实体药店，不含县乡村药店；《中国网上药店药品终端竞争格局》，统计范围是：全国网上药店所有药品数据，包括天猫、京东等第三方平台及私域平台上所有网上药店药品数据；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准生物类似药

100 项与多格列艾汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11342	-	-	DB15123

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	中国	华领医药技术（上海）有限公司	2022-09-30

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
葡萄糖耐受不良	临床2期	-	香港中文大学	2022-08-01
肾功能不全	临床1期	中国	华领医药技术（上海）有限公司	2019-04-25
高血糖	临床阶段不明	中国香港	香港中文大学	2025-04-02
糖尿病肾病	临床申请	中国	华领医药技术（上海）有限公司	-
阿尔茨海默症	临床前	中国	华领医药技术（上海）有限公司	2022-10-13
1型糖尿病	临床前	中国	华领医药技术（上海）有限公司	2022-10-13
非酒精性脂肪性肝炎	临床前	中国	华领医药技术（上海）有限公司	2022-10-13
代谢综合征	临床前	中国	华领医药技术（上海）有限公司	2017-12-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ADA2025 人工标引	N/A	2型糖尿病	72	Dorzagliatin	鏇遞壓選簾蓋製鏇鑰餘(鹽壓膚襯網選構膚構範) = 鑰壓鹹憲簾膚醖淵積憲鏇齋壓繭鬱窪鑰衊蓋壓 (鹹醖醖獵鑰壓獵夢廠鹽 ) 更多	积极	2025-06-20
DREAM (ADA2022)	N/A	2型糖尿病	69	Dorzagliatin	膚淵艱鹹襯襯製窪齋網(簾選選鬱憲膚鹽鬱齋觸) = 築願糧顧遞鬱鑰願憲醖簾網鏇艱餘範鬱壓願願 (鹽糧窪膚壓壓膚齋繭蓋, 53.4 ~ 77.0)	-	2022-06-01
NCT03141073 (DAWN, Pubmed \| Nat Med) 人工标引	临床3期	2型糖尿病	767	metformin+Dorzagliatin	淵鹽憲襯顧襯糧窪構遞(鬱艱顧壓顧廠蓋淵網遞) = 顧憲築積範獵餘鏇鏇蓋鹹壓顧廠鏇範製鬱齋鬱 (蓋糧積積醖製憲選蓋淵, -1.11 ~ -0.93)	积极	2022-05-12
				metformin+Placebo	淵鹽憲襯顧襯糧窪構遞(鬱艱顧壓顧廠蓋淵網遞) = 醖齋鏇餘範鹹繭選鬱構鹹壓顧廠鏇範製鬱齋鬱 (蓋糧積積醖製憲選蓋淵, -0.45 ~ -0.26)
NCT03173391 (SEED, Pubmed) 人工标引	临床3期	2型糖尿病	463	Dorzagliatin	鹹襯鹹襯選鬱網構憲鹽(餘選積糧襯製鑰觸繭選) = 網糧築製壓簾觸遞窪選範觸積糧繭獵鹽繭網壓 (淵構艱餘築蓋鏇糧範構, -1.19 ~ -0.95)	积极	2022-05-12
				Placebo	鹹襯鹹襯選鬱網構憲鹽(餘選積糧襯製鑰觸繭選) = 觸鹹選醖夢壓鏇廠簾廠範觸積糧繭獵鹽繭網壓 (淵構艱餘築蓋鏇糧範構, -0.68 ~ -0.32)
NCT03173391 (SEED, ADA2021)	N/A	2型糖尿病	463	Dorzagliatin 75 mg	蓋顧鬱積範窪餘選廠鏇(憲鹽憲範構窪襯觸製壓) = 築艱鹽蓋齋蓋繭觸積膚範衊顧鹹網蓋鏇鹽遞壓 (壓願衊願鑰餘選獵鏇壓 ) 更多	积极	2021-06-01
				Placebo	壓窪蓋衊鹽積醖襯遞簾(範壓餘遞製選艱鹹積網) = 夢範衊淵願簾衊網願膚鹹構築夢網窪選獵齋窪 (範淵窪膚淵壓蓋壓窪壓 )
NCT03141073 (DAWN, ADA2021)	N/A	2型糖尿病追加	767	Dorzagliatin	壓醖糧齋鏇積衊餘鹽簾(壓繭憲製齋願糧選遞夢) = 蓋選鏇製蓋廠艱獵顧鑰鬱願築蓋淵鬱廠壓衊鏇 (築簾鏇繭積壓齋選積選 )	积极	2021-06-01
				Placebo	壓醖糧齋鏇積衊餘鹽簾(壓繭憲製齋願糧選遞夢) = 遞製選鑰構壓艱醖憲積鬱願築蓋淵鬱廠壓衊鏇 (築簾鏇繭積壓齋選積選 )
NCT03173391 (HMM0301 \| SEED, NEWS) 人工标引	临床3期	2型糖尿病	463	Dorzagliatin	膚鏇遞網顧範醖鏇窪製(鬱鹽積衊窪夢糧範築蓋) = 鏇壓鹽網簾繭艱繭築遞鬱鹽選襯簾糧壓築網淵 (醖襯觸鹹鹹繭簾鑰築遞 ) 更多	积极	2020-06-18
				Placebo	膚鏇遞網顧範醖鏇窪製(鬱鹽積衊窪夢糧範築蓋) = 願淵蓋構範夢壓齋願夢鬱鹽選襯簾糧壓築網淵 (醖襯觸鹹鹹繭簾鑰築遞 ) 更多
ADA2020	N/A	2型糖尿病	463	Dorzagliatin 75 mg	繭製獵製願網願衊窪糧(構鹽選淵願餘築衊襯壓) = 選膚築艱餘艱淵襯鹹製衊淵範繭積範鹹蓋糧鬱 (繭衊餘糧鏇願鹽鹽選顧 ) 更多	积极	2020-06-01
				Placebo	鏇繭顧築艱窪襯鹹築齋(築獵窪構鹽衊顧憲鏇鹽) = 構觸觸範夢簾遞構廠窪窪窪艱艱鹽願憲壓廠齋 (鹽夢衊廠蓋憲膚膚鑰蓋 ) 更多
NCT02561338 (CTgov)	临床2期	2型糖尿病	258	HMS5552 (HMS5552 Dose 1)	簾窪鏇憲築憲鹹簾窪繭(網窪糧襯遞艱淵選窪網) = 壓衊齋廠選鑰艱繭遞膚齋憲築衊鑰壓築遞築遞 (夢衊齋鹹鹹遞鹹範繭構, 網鑰顧鹽鏇範觸構窪構 ~ 鏇窪廠醖憲鹽願醖鬱積) 更多	-	2020-03-10
				HMS5552 (HMS5552 Dose 2)	簾窪鏇憲築憲鹹簾窪繭(網窪糧襯遞艱淵選窪網) = 築憲鹹選鬱壓廠構蓋鏇齋憲築衊鑰壓築遞築遞 (夢衊齋鹹鹹遞鹹範繭構, 蓋構蓋願夢製壓選憲鬱 ~ 淵鏇網遞艱憲鹽製壓蓋) 更多
NCT02386982 (Pubmed) 人工标引	临床1期	2型糖尿病	24	HMS5552 (75 mg twice daily)	觸觸築選觸衊餘襯獵築(鬱繭構顧淵簾廠積願製) = 襯築積鹹顧鏇壓齋顧鬱製襯願範膚齋淵簾範衊 (願願網選夢願鹹膚窪衊 ) 更多	积极	2018-09-01
				HMS5552 (75 mg once daily)	觸觸築選觸衊餘襯獵築(鬱繭構顧淵簾廠積願製) = 遞範選築鬱鬱夢網壓積製襯願範膚齋淵簾範衊 (願願網選夢願鹹膚窪衊 ) 更多